Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04770610 · ClinicalTrials.gov registry record · Phase 3
Study of OT-101 in Treating Myopia
A Phase 3 study of Myopia, Progressive, sponsored by Ocumension (Hong Kong) Limited.
- Active
- Registry status
- Phase 3
- Development phase
- 678
- Enrollment target
- 15
- Study locations
NCT04770610: Active Phase 3 study of Myopia, Progressive, sponsored by Ocumension (Hong Kong) Limited.
NCT04770610 is a Phase 3 study of Myopia, Progressive that is active but no longer recruiting, run by Ocumension (Hong Kong) Limited. The registered enrollment target is 678 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (12% lower). The trial reports 15 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04770610, a Phase 3 study of Myopia, Progressive, is active but no longer recruiting, sponsored by Ocumension (Hong Kong) Limited.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 678 participants
- Enrollment target
- 15
- Study locations
Study Summary
This is a phase III, randomized, double-masked, placebo-controlled, parallel-group, multicenter safety, tolerability, and efficacy study of atropine sulfate 0.01% (OT-101) as an investigational treatment for myopia in pediatric subjects
Primary Outcome
Efficacy of OT-101 Ophthalmic Solution
Conditions Studied
Interventions
- DRUG Vehicle
- DRUG OT-101 Ophthalmic Solution
Study Locations (15)
Pennsylvania
- Scott & Christie and Associates - Cranberry Township
- Pediatric Ophthalmology of Erie, Inc - Erie
- UPMC Children's Hospital - Pittsburgh
Colorado
- Colorado Vision Institute - Colorado Springs
- Eye Center of Northern Colorado, PC - Fort Collins
Florida
- Family Focus - Gainesville
- Pediatric Eye Consultants of North Florida - Jacksonville
North Carolina
- Pure Ophthalmic Research - Mint Hill
- CORE, Inc. - Shelby
Indiana
- Indiana University Health Physicians Pediatric Ophthalmology - Indianapolis
Maryland
- Kids Eye Care of Maryland - Rockville
Missouri
- Comprehensive Eye Care, Ltd. - Washington
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 678 participants |
| Start Date | 2021-04-01 |
| Est. Completion | 2027-04 |
| Phase | Phase 3 |
What the registry record for NCT04770610 still lists
NCT04770610 is an interventional study that assigns participants to a tested intervention. The registered 678 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (12% lower).
The record links to 1 condition, with Myopia, Progressive appearing as the primary indexed condition, and to 2 interventions - of which Vehicle is the first listed.
NCT04770610 lists 15 locations in 10 states (Pennsylvania, Colorado, Florida).
Frequently Asked Questions
What is clinical trial NCT04770610 about?
NCT04770610 is a clinical study titled "Study of OT-101 in Treating Myopia". This is a phase III, randomized, double-masked, placebo-controlled, parallel-group, multicenter safety, tolerability, and efficacy study of atropine sulfate 0.01% (OT-101) as an investigational treatment for myopia in pediatric subjects
What is the current status of trial NCT04770610?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 678 participants. The study started on 2021-04-01. Estimated completion is 2027-04.
What conditions does trial NCT04770610 study?
This clinical trial studies the following conditions: Myopia, Progressive.
What interventions are being tested in trial NCT04770610?
The interventions under investigation include: Vehicle (DRUG), OT-101 Ophthalmic Solution (DRUG).
Who is sponsoring clinical trial NCT04770610?
This trial is sponsored by Ocumension (Hong Kong) Limited, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04770610 being conducted?
This trial has 15 study locations across Colorado, Florida, Indiana, Maryland, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myopia, Progressive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04770610's enrollment target sits among peer trials
678 536th of 2000 higher than 1,465 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05372484 · 678 participants · NA
Rice Technologies for Cervical Cancer Screening and Diagnosis
- NCT06436924 · 678 participants
Safety and Efficacy of Workflows of High Volume Single Operators in a LAAO Device Implant Procedural Day
- NCT03501706 · 680 participants · NA
An Assessment of Cognitive Improvement Training Among Mid-life Individuals
- NCT05626452 · 680 participants · NA
PrEP Optimization Among Women to Enhance Retention and Uptake
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI